ClinicalTrials.gg
CompletedNCT07442591Updated Sep 23, 2026

A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants

A Phase 1 interventional study of Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) and Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) in Healhty, sponsored by Shanghai WD Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Shanghai WD Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603.

The main question we want to answer is:

  • How does the body process WD-1603 when it is taken by different time intervals? What will participants do?
  • Participants will take one tablet of WD-1603 twice a day on three separate days.
  • On each dosing day, the two doses will be spaced different hours apart.
  • Between each dosing day, there will be a rest period of up to 7 days.
Read the detailed description

This trial is a multiple-dose, open-label, sequential, three-period pharmacokinetic study comparing different dosing intervals of WD-1603 in healthy participants.

The purpose of the study is:

  • To evaluate the effect of different dosing intervals on the pharmacokinetics of twice-daily WD-1603 when administered before meals.
  • To assess the safety and tolerability of WD-1603 in healthy participants. Each participant will receive the investigational drug in the sequence of Treatment A, Treatment B, and Treatment C. After each dosing period, there will be a washout period of up to 7 days.

This Phase I clinical trial is planned to enroll 12 healthy participants, with an appropriate proportion of female participants (at least one quarter, i.e., 3 participants).

Pharmacokinetic parameters will be calculated using Phoenix WinNonlin (version 8.3 or higher), and other analyses will be performed using SAS software (version 9.4 or higher). Using PKS, an analysis of variance (ANOVA) is performed on the natural log-transformed Cmax, AUC0-τ, and ΔC0.5. The model includes dosing occasion as a fixed effect and participant as a random effect. The 90% confidence interval for the geometric mean ratio (second dose/first dose) of each parameter is calculated.

02

Conditions studied

  • Healhty

Keywords

  • multiple-dose, open-label, pharmacokinetic
03

In context

Lead sponsor

Shanghai WD Pharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female participants aged 18 to 55 years (inclusive) at the time of signing the form (ICF).
  • Body weight: male ≥ 50 kg, female ≥ 45 kg; (BMI) between 18 and 27 kg/m² (inclusive) (BMI = weight [kg] / height² [m²]).
  • Medical history inquiry, physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood biochemistry, serological virology tests, coagulation function), 12-lead , intraocular pressure measurement, abdominal ultrasound, and chest X-ray during the screening period are all within normal ranges or clinically insignificant if outside normal ranges.
  • Participants (including their spouses or partners) have no plans for conception or for donating sperm/eggs from the time of signing the ICF (for females)/first dosing (for males) until 3 months after the last dose, and voluntarily agree to use effective non-pharmacological during the trial period.
  • Fully understand the trial content, procedures, and potential adverse reactions, voluntarily agree to participate, and sign the ICF before any trial-related procedures begin.
  • Able to communicate well with the investigators and capable of understanding and complying with the requirements of this trial.

Exclusion criteria

Exclusion Criteria:

  • Allergy-prone constitution, history of allergic diseases, or known severe allergic reaction or allergy history to levodopa/carbidopa or related medications.
  • Drug use within 3 months prior to screening, history of drug abuse, or positive urine drug abuse screening (morphine, methamphetamine, ketamine, methylenedioxymethamphetamine, tetrahydrocannabinol acid, cocaine).
  • History of glaucoma, cancer, diabetes mellitus, bronchial asthma, or any cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, hematological, dermatological, endocrine, neuropsychiatric diseases, or other significant conditions.
  • Dysphagia or any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy), or gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome.
  • History of orthostatic hypotension.
  • Any relevant medical history, surgical history, or trauma within 3 months prior to the first dose that may affect trial safety or drug pharmacokinetics, or planned surgery during the trial period.
  • Use of prescription drugs, over-the-counter medications, health products, Chinese herbal medicines, or dietary supplements within 4 weeks prior to the first dose, especially monoamine oxidase inhibitors (e.g., phenelzine, rasagiline, selegiline, brofaromine, toloxatone, isocarboxazid, etc.).
  • Participation in any clinical trial and receipt of drugs within 3 months prior to the first dose.
  • Blood donation (including component blood) or significant blood loss (≥400 mL), blood transfusion, or use of blood products within 3 months prior to the first dose.
  • Difficulty with venous access, unsuitability or unwillingness to use intravenous catheters, or history of needle/blood phobia.
  • Heavy smokers or average daily cigarette consumption of more than 10 cigarettes within 3 months prior to screening.
  • Alcohol consumption exceeding 21 standard units per week within 3 months prior to screening (1 standard unit contains 14g of alcohol, e.g., 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), positive alcohol breath test, or unwillingness to abstain from alcohol from 48 hours before the first dose of each period until the completion of blood sampling for that period.
  • Estimated (eGFR) \< 90 mL/min·1.73m² during the screening period.
  • During screening: systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, diastolic blood pressure \< 60 mmHg or ≥ 90 mmHg, pulse rate > 100 beats/min or \< 50 beats/min.
  • History of prolonged or other clinically significant cardiac diseases, or QTcF ≥ 450 ms on during screening.
  • Symptoms of acute infection (e.g., influenza) or acute gastroenteritis within 2 weeks prior to screening, or history of vomiting or diarrhea within 1 week prior to screening.
  • Positive for surface antigen (HBsAg), virus antibody (HCV-Ab), antibody (HIV-Ab), or Treponema pallidum antibody.
  • Currently pregnant (including positive pregnancy test) or lactating female.
  • Poor compliance as judged by the investigator, or other factors deemed unsuitable for participation in this trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    WD-1603 (25 mg/150 mg) 5-hour interval

    Cohort 1: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 5-hour interval between doses, over a 1-day dosing period.

    Drug: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)

  • Experimental
    WD-1603 (25 mg/150 mg) 6-hour interval

    Cohort 2: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 6-hour interval between doses, over a 1-day dosing period.

    Drug: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)

  • Experimental
    WD-1603 (25 mg/150 mg) 7-hour interval

    Cohort 3: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 7-hour interval between doses, over a 1-day dosing period.

    Drug: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)

Interventions

  • DrugCarbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)

    Administered twice daily for one day with a 5-hour interval between doses.

  • DrugCarbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)

    Administered twice daily for one day with a 6-hour interval between doses.

  • DrugCarbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)

    Administered twice daily for one day with a 7-hour interval between doses.

06

What researchers measure

Primary outcomes

  1. Maximal Plasma Concentration (Cmax) of Carbidopa and Levodopa

    Maximal plasma concentration (Cmax) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  2. Area under the Concentration versus Time Curve from 0 to Time t (AUC0-t) of Carbidopa and Levodopa

    Area under the concentration versus time curve from 0 to time t (AUC0-t) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  3. Area under the Concentration versus Time Curve from 0 Extrapolated to Infinity (AUC0-∞) of Carbidopa and Levodopa

    Area under the concentration versus time curve from 0 extrapolated to infinity (AUC0-∞) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  4. Time to Maximal Plasma Concentration (tmax) of Carbidopa and Levodopa

    Time to maximal plasma concentration (tmax) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  5. Elimination Half-life (t1/2) of Carbidopa and Levodopa

    Elimination half-life (t1/2) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  6. Terminal Elimination Rate Constant (λz) of Carbidopa and Levodopa

    Terminal elimination rate constant (λz) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  7. Apparent Clearance (CL/F) of Carbidopa and Levodopa

    Apparent clearance (CL/F) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  8. Apparent Volume of Distribution (Vd/F) of Carbidopa and Levodopa

    Apparent volume of distribution (Vd/F) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  9. Cmax of Levodopa and Carbidopa for Each Dose

    Cmax of carbidopa and levodopa for each dose after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.

    Time frame: 24 hours after the first dose.

  10. AUC0-τ of Levodopa and Carbidopa for Each Dose

    AUC0-τ of carbidopa and levodopa for each dose after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants, where τ is the dosing interval.

    Time frame: 24 hours after the first dose.

  11. Ratio of ΔC0.5 between the Two Doses

    Ratio of ΔC0.5 of carbidopa and levodopa between the two doses after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants, where the ΔC0.5 of the first dose is equal to the concetration at 0.5 hour C0.5; the ΔC0.5 of the second dose is the difference between the concontration at t+0.5 hours (Ct+0.5) and the concentration at t (Ct) (t is the dosing interval).

    Time frame: 24 hours after the first dose.

Secondary outcomes

  1. Number and Percentage of Participants for Each Type of Adverse Events (AEs)

    All AEs will be coded using MedDRA version 28.1 or higher to provide the System Organ Class (SOC) and Primary Term (PT) for each event. AEs will be summarized by treatment period, including the number and percentage of participants for each event category and for treatment-related adverse events. Additionally, summarize treatment-emergent adverse events (TEAEs) by treatment period for deaths, serious adverse events (SAEs), events leading to discontinuation of study medication, and events leading to early termination of the study.

    Time frame: Throughout the study, about 21 days.

  2. Number and Percentage of Participants with Abnormal Findings in Laboratory Tests, Physical Examinations, Vital Signs and 12-lead Electrocardiogram (12-lead ECG)

    Summarize measurements recorded at each time point (screening, baseline, each visit, and study completion) along with changes from baseline at each visit and study completion. Use cross-tabulation to summarize baseline values for each indicator and the most clinically significant change determined post-treatment.

    Time frame: Baseline, 1 week, 2 weeks and 3 weeks.

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, China
08

References and documents

Publications

  • 中华医学会神经病学分会帕金森病及运动障碍学组 and 中国医师协会神经内科医师分会帕金森病及运动障碍学组, 中国帕金森病治疗指南(第四版). 中华神经科杂志, 2020. 53(12): p. 973-986.
  • Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):718-23. doi: 10.1136/jnnp.52.6.718. PubMed 2501456 ↗
  • Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021 Sep 29;26(19):5905. doi: 10.3390/molecules26195905. PubMed 34641447 ↗
  • Buril J, Burilova P, Pokorna A, Kovacova I, Balaz M. Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic-A nationwide retrospective study. PLoS One. 2021 Feb 2;16(2):e0246342. doi: 10.1371/journal.pone.0246342. eCollection 2021. PubMed 33529251 ↗
  • Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-905. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1. PubMed 28150045 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Apr 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Mar 2, 2026
StartActual
Mar 17, 2026
Primary completionActual
Apr 23, 2026
CompletionActual
Apr 23, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442591
Lead sponsor
Shanghai WD Pharmaceutical Co., Ltd.
Collaborators
Xuhui Central Hospital, Shanghai, BalGenSource Medical Technology Co. Ltd., Shanghai Xihua Scientific Co., Ltd., Shanghai BioGuider Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Mar 17, 2026
Primary completion
Apr 23, 2026
Completion
Apr 23, 2026
Last update
Sep 23, 2026

Study contacts

Yanmei Liu, Master
principal investigator · Xuhui Central Hospital, Shanghai

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion